Cargando…
Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
BACKGROUND: Immunotherapies that target immune-checkpoint molecules such PD-1 have helped to achieve durable responses in melanoma treatment. However, 25% of melanoma patients who showed objective responses to PD-1 blockade develop resistance and suffer from disease progression and ultimately death,...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836392/ https://www.ncbi.nlm.nih.gov/pubmed/29515691 http://dx.doi.org/10.1186/s41232-018-0060-2 |
_version_ | 1783303956115488768 |
---|---|
author | Han, Nanumi Baghdadi, Muhammad Ishikawa, Kozo Endo, Hiraku Kobayashi, Takuto Wada, Haruka Imafuku, Keisuke Hata, Hiroo Seino, Ken-ichiro |
author_facet | Han, Nanumi Baghdadi, Muhammad Ishikawa, Kozo Endo, Hiraku Kobayashi, Takuto Wada, Haruka Imafuku, Keisuke Hata, Hiroo Seino, Ken-ichiro |
author_sort | Han, Nanumi |
collection | PubMed |
description | BACKGROUND: Immunotherapies that target immune-checkpoint molecules such PD-1 have helped to achieve durable responses in melanoma treatment. However, 25% of melanoma patients who showed objective responses to PD-1 blockade develop resistance and suffer from disease progression and ultimately death, which necessitates the identification of related resistance mechanisms. IL-34 is a cytokine that controls the biology of myeloid cell lineage through binding to CSF-1R. IL-34 is importantly involved in the pathogenesis of various diseases. In cancer, the expression of IL-34 has been suggested to associate with tumor growth, metastasis, angiogenesis, and therapeutic resistance such as in lung cancers and malignant pleural mesotheliomas. In this study, we evaluate the possible involvement of IL-34 in immunotherapeutic resistance. CASE PRESENTATION: Melanoma resection species were obtained from a patient who developed a refractory melanoma against immunotherapy with Nivolumab, and stained with anti-IL-34, anti-melanoma antigens and anti-CD163 antibody. Staining of these markers was compared between primary or metastatic refractory melanoma tissues. Immunohistochemistry staining of melanoma tissues showed an enhanced expression of IL-34 in metastatic refractory melanoma compared to primary melanoma tissues, which correlates with increased frequencies of CD163(+) macrophages. CONCLUSION: We introduce for the first time a clinical case of a patient with metastatic refractory melanoma that acquired resistance to anti-PD-1 immunotherapy, showing an enhanced expression of IL-34 in refractory melanoma tissues. |
format | Online Article Text |
id | pubmed-5836392 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-58363922018-03-07 Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma Han, Nanumi Baghdadi, Muhammad Ishikawa, Kozo Endo, Hiraku Kobayashi, Takuto Wada, Haruka Imafuku, Keisuke Hata, Hiroo Seino, Ken-ichiro Inflamm Regen Case Report BACKGROUND: Immunotherapies that target immune-checkpoint molecules such PD-1 have helped to achieve durable responses in melanoma treatment. However, 25% of melanoma patients who showed objective responses to PD-1 blockade develop resistance and suffer from disease progression and ultimately death, which necessitates the identification of related resistance mechanisms. IL-34 is a cytokine that controls the biology of myeloid cell lineage through binding to CSF-1R. IL-34 is importantly involved in the pathogenesis of various diseases. In cancer, the expression of IL-34 has been suggested to associate with tumor growth, metastasis, angiogenesis, and therapeutic resistance such as in lung cancers and malignant pleural mesotheliomas. In this study, we evaluate the possible involvement of IL-34 in immunotherapeutic resistance. CASE PRESENTATION: Melanoma resection species were obtained from a patient who developed a refractory melanoma against immunotherapy with Nivolumab, and stained with anti-IL-34, anti-melanoma antigens and anti-CD163 antibody. Staining of these markers was compared between primary or metastatic refractory melanoma tissues. Immunohistochemistry staining of melanoma tissues showed an enhanced expression of IL-34 in metastatic refractory melanoma compared to primary melanoma tissues, which correlates with increased frequencies of CD163(+) macrophages. CONCLUSION: We introduce for the first time a clinical case of a patient with metastatic refractory melanoma that acquired resistance to anti-PD-1 immunotherapy, showing an enhanced expression of IL-34 in refractory melanoma tissues. BioMed Central 2018-03-05 /pmc/articles/PMC5836392/ /pubmed/29515691 http://dx.doi.org/10.1186/s41232-018-0060-2 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Han, Nanumi Baghdadi, Muhammad Ishikawa, Kozo Endo, Hiraku Kobayashi, Takuto Wada, Haruka Imafuku, Keisuke Hata, Hiroo Seino, Ken-ichiro Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma |
title | Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma |
title_full | Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma |
title_fullStr | Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma |
title_full_unstemmed | Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma |
title_short | Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma |
title_sort | enhanced il-34 expression in nivolumab-resistant metastatic melanoma |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836392/ https://www.ncbi.nlm.nih.gov/pubmed/29515691 http://dx.doi.org/10.1186/s41232-018-0060-2 |
work_keys_str_mv | AT hannanumi enhancedil34expressioninnivolumabresistantmetastaticmelanoma AT baghdadimuhammad enhancedil34expressioninnivolumabresistantmetastaticmelanoma AT ishikawakozo enhancedil34expressioninnivolumabresistantmetastaticmelanoma AT endohiraku enhancedil34expressioninnivolumabresistantmetastaticmelanoma AT kobayashitakuto enhancedil34expressioninnivolumabresistantmetastaticmelanoma AT wadaharuka enhancedil34expressioninnivolumabresistantmetastaticmelanoma AT imafukukeisuke enhancedil34expressioninnivolumabresistantmetastaticmelanoma AT hatahiroo enhancedil34expressioninnivolumabresistantmetastaticmelanoma AT seinokenichiro enhancedil34expressioninnivolumabresistantmetastaticmelanoma |